George D Demetri

List of Publications by Year
in descending order

90	22,244	76326 40	62596 80
papers	citations	h-index	g-index

91	91	91	18939
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015â€“2020. Clinical Cancer Research, 2022, 28, 27-35.	7.0	22
2	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clinical Cancer Research, 2022, 28, 1302-1312.	7.0	74
3	Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression. Clinical Cancer Research, 2022, 28, 2397-2408.	7.0	6
4	Abstract 5648: Response and resistance to CDK2 and CDK4/6 inhibition in GIST. Cancer Research, 2022, 82, 5648-5648.	0.9	0
5	FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs. Clinical Cancer Research, 2021, 27, 916-921.	7.0	4
6	Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clinical Cancer Research, 2021, 27, 1695-1705.	7.0	19
7	HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2021, 27, 1706-1719.	7.0	14
8	Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibodyâ€“Drug Conjugate. Cancer Discovery, 2021, 11, 1508-1523.	9.4	20
9	First-in-Human Phase I Study of ABBV-085, an Antibodyâ€“Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 3556-3566.	7.0	21
10	Ultraâ€rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer, 2021, 127, 2934-2942.	4.1	96
11	Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Medicine, 2021, 10, 3565-3574.	2.8	6
12	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1â€“2 trials. Lancet Oncology, The, 2020, 21, 271-282.	10.7	1,034
13	A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. European Journal of Cancer, 2020, 126, 21-32.	2.8	16
14	Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes. Molecular Cancer Research, 2020, 18, 1302-1314.	3.4	24
15	Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers. Future Oncology, 2020, 16, 417-425.	2.4	19
16	LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications. Cancers, 2020, 12, 757.	3.7	18
17	The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nature Medicine, 2020, 26, 181-187.	30.7	158
18	Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1. JCO Precision Oncology, 2020, 4, 79-90.	3.0	27

#	Article	IF	Citations
19	The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments. Expert Review of Anticancer Therapy, 2020, 20, 29-39.	2.4	10
20	Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. BMC Cancer, 2019, 19, 794.	2.6	20
21	The effect of gastrectomy on regorafenib exposure and progressionâ€free survival in patients with advanced gastrointestinal stromal tumours. British Journal of Clinical Pharmacology, 2019, 85, 2399-2404.	2.4	5
22	Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer, 2019, 125, 4435-4441.	4.1	10
23	Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature, 2019, 575, 229-233.	27.8	164
24	Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor. , 2019, 7, 296.		11
25	Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2019, 25, 7287-7293.	7.0	37
26	Overall survival and histologyâ€specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer, 2019, 125, 2610-2620.	4.1	47
27	Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma. Clinical Cancer Research, 2019, 25, 5135-5142.	7.0	14
28	Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. British Journal of Cancer, 2019, 120, 612-620.	6.4	109
29	Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer Research, 2019, 79, 994-1009.	0.9	17
30	Efficacy of Larotrectinib inTRKFusionâ€“Positive Cancers in Adults and Children. New England Journal of Medicine, 2018, 378, 731-739.	27.0	2,036
31	Evolution of the International Sarcoma Community: A Personal Perspective. Oncology, 2018, 95, 1-4.	1.9	7
32	Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial. BMC Cancer, 2018, 18, 790.	2.6	7
33	Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5746-E5755.	7.1	20
34	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity, 2017, 46, 197-204.	14.3	400
35	MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nature Communications, 2017, 8, 14674.	12.8	53
36	Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results. JAMA Oncology, 2017, 3, 944.	7.1	73

#	Article	IF	Citations
37	SMARCB1 is required for widespread BAF complexâ€“mediated activation of enhancers and bivalent promoters. Nature Genetics, 2017, 49, 1613-1623.	21.4	207
38	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell, 2017, 171, 950-965.e28.	28.9	738
39	Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecologic Oncology, 2017, 146, 531-537.	1.4	51
40	Clinical evidence from two phase 3 trials supporting statistical adjustment methods to assess confounding impact of treatment crossover on overall survival (OS).. Journal of Clinical Oncology, 2017, 35, e22509-e22509.	1.6	0
41	Personalized Comments on Challenges and Opportunities in Kidney Disease Therapeutics: The Glom-NExT Symposium. Seminars in Nephrology, 2016, 36, 448.	1.6	2
42	Tales of Personalized Cancer Treatment. Seminars in Nephrology, 2016, 36, 462-467.	1.6	0
43	Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. European Journal of Cancer, 2016, 61, 94-101.	2.8	25
44	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet, The, 2016, 387, 1629-1637.	13.7	610
45	Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. Journal of Clinical Oncology, 2016, 34, 786-793.	1.6	647
46	Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget, 2016, 7, 16581-16592.	1.8	57
47	Whole Lung Irradiation in Adults with Metastatic Ewing Sarcoma: Practice Patterns and Implications for Treatment. Sarcoma, 2015, 2015, 1-5.	1.3	6
48	Cardio-Oncology. Circulation, 2015, 132, 2248-2258.	1.6	99
49	Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. International Journal of Clinical Oncology, 2015, 20, 905-912.	2.2	27
50	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. Oncologist, 2015, 20, 823-830.	3.7	26
51	Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncology, The, 2015, 16, 550-560.	10.7	96
52	Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2015, 16, 531-540.	10.7	56
53	Biologic Activity of Autologous, Granulocyteâ€“Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clinical Cancer Research, 2015, 21, 3178-3186.	7.0	34
54	Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. European Journal of Cancer, 2014, 50, 2162-2170.	2.8	82

#	Article	IF	Citations
55	Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nature Genetics, 2014, 46, 601-606.	21.4	142
56	Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer, 2014, 120, 738-743.	4.1	84
57	Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. European Journal of Cancer, 2014, 50, 981-986.	2.8	29
58	Antiproliferative Effects of CDK4/6 Inhibition inCDK4-Amplified Human LiposarcomaIn VitroandIn Vivo. Molecular Cancer Therapeutics, 2014, 13, 2184-2193.	4.1	102
59	International expert opinion on patient-tailored management of soft tissue sarcomas. European Journal of Cancer, 2014, 50, 679-689.	2.8	40
60	Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. Journal of Clinical Oncology, 2014, 32, 1563-1570.	1.6	252
61	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, The, 2013, 381, 295-302.	13.7	1,144
62	Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor. Annals of Surgery, 2013, 258, 422-429.	4.2	150
63	Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors. F1000Research, 2013, 2, 152.	1.6	2
64	Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure. Clinical Cancer Research, 2012, 18, 3170-3179.	7.0	116
65	Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, The, 2012, 379, 1879-1886.	13.7	1,752
66	Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors. Clinical Cancer Research, 2011, 17, 871-879.	7.0	150
67	NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, S-1-S-41.	4.9	1,004
68	Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor. New England Journal of Medicine, 2010, 363, 1727-1733.	27.0	769
69	Disease state awareness in sarcoma. Clinical Advances in Hematology and Oncology, 2010, 8, 543-5.	0.3	0
70	Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules. Journal of Clinical Oncology, 2009, 27, 4188-4196.	1.6	472
71	Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure. Clinical Cancer Research, 2009, 15, 5902-5909.	7.0	133
72	Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2008, 26, 5352-5359.	1.6	693

#	Article	IF	Citations
73	Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncology, The, 2007, 8, 595-602.	10.7	416
74	A Novel Role for CpG Oligonucleotides in Tumor Immunotherapy: CpG-ODN Induce Targeted Chemokine-Induced Lymphocyte Migration to the Peripheral Tissues in Humans.. Blood, 2007, 110, 1791-1791.	1.4	0
75	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, The, 2006, 368, 1329-1338.	13.7	2,349
76	Case 32-2004. New England Journal of Medicine, 2004, 351, 1779-1787.	27.0	9
77	Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. New England Journal of Medicine, 2002, 347, 472-480.	27.0	4,018
78	Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Hematology/Oncology Clinics of North America, 2002, 16, 1115-1124.	2.2	56
79	Challenges in Oncology. Journal of Clinical Oncology, 2002, 20, 870-872.	1.6	34
80	ET-743: the US experience in sarcomas of soft tissues. Anti-Cancer Drugs, 2002, 13 Suppl 1, S7-9.	1.4	12
81	STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene, 2001, 20, 5054-5058.	5.9	643
82	Two Patients With Sarcoma. Journal of Clinical Oncology, 2000, 18, 2343-2344.	1.6	1
83	Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. , 1999, 86, 1621-1627.		13
84	Long-Term Outcomes After Function-Sparing Surgery Without Radiotherapy for Soft Tissue Sarcoma of the Extremities and Trunk. Journal of Clinical Oncology, 1999, 17, 3252-3259.	1.6	194
85	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors. , 1998, 83, 409-414.		37
86	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors. , 1998, 83, 409.		1
87	Changes in Tc-99m radionuclide bone scan images and peripheralizatioin of marrow hematopoetic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. Cancer, 1994, 74, 1887-1890.	4.1	8
88	Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. British Journal of Haematology, 1994, 87, 153-161.	2.5	30
89	Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). , 0, .		1
90	Derivation and validation of a risk classification tree for patients with synovial sarcoma. Cancer Medicine, 0, , .	2.8	2